Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SIGY Sigyn Therapeutics Inc (QB)

0.00 (0.0%)
Last Updated: 11:12:53
Delayed by 15 minutes


Draw Mode:

Volume 0.00
Bid Price 0.14
Ask Price 0.20
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Sigyn Therapeutics Inc (QB) SIGY OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.195 11:12:53
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0.00 - 0.052 - 0.48
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.195 USD

Sigyn Therapeutics Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 8.62M 44.22M 8.63M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Sigyn Therapeutics (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No SIGY Message Board. Create One! See More Posts on SIGY Message Board See More Message Board Posts

Historical SIGY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.1760.1950.140.161293410,5670.01910.8%
1 Month0.1410.1950.140.1556539,3170.05438.3%
3 Months0.,576-0.005-2.5%
6 Months0.0850.320.0520.162672311,1580.11129.41%
1 Year0.24990.480.0520.2196117,346-0.0549-21.97%
3 Years1.553.500.0520.52092756,747-1.36-87.42%
5 Years1.85013.500.0520.55131586,309-1.66-89.46%

Sigyn Therapeutics (QB) Description

Sigyn Therapeutics is a development-stage company focused on creating therapeutic solutions to address unmet needs in global health. Sigyn Therapy, the Companys lead product candidate, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders that are not addressed with approved drug therapies. Candidate treatment indications for Sigyn Therapy include chronic inflammation and endotoxemia in end-stage renal disease patients, sepsis (leading cause of hospital deaths), community acquired pneumonia (a leading cause of death among infectious diseases), and emerging pandemic threats. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the delivery of FDA approved chemotherapeutic agents and ChemoPure to reduce chemotherapy toxicity.

Your Recent History

Delayed Upgrade Clock